Physician profile
John J Lee
NPI 1356357644
$4,214.86
in general payments reported to CMS, 2019-2025
29 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $367 · 2021: $311 · 2022: $627 · 2023: $623 · 2024: $624 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $750.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $698.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $456.21 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $358.18 | 2022 | |
| Amgen INC. | $350.79 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.53 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $173.38 | 2024 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $140.41 | 2020-2025 | Camzyos |
| Pfizer INC. | $137.89 | 2019-2023 | |
| Angiodynamics, INC. | $112.69 | 2019-2024 | Venacure 1470 Pro, Angiovac |
| Alnylam Pharmaceuticals INC. | $97.61 | 2019-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.15 | 2023-2025 | Jardiance |
| Medtronic, INC. | $88.84 | 2021-2025 | Symplicity G3, Venaseal |
| Sanofi-Aventis U.S. LLC | $69.75 | 2019-2023 | |
| Boston Scientific Corporation | $69.67 | 2021-2025 | Varithena Administration Pack, Watchman Flx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $62.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.20 | 2022-2024 | Winrevair |
| Daiichi Sankyo INC. | $49.80 | 2023-2024 | Injectafer |
| Cleerly, INC. | $49.55 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Astellas Pharma US INC | $35.84 | 2021 | |
| Amarin Pharma, INC. | $34.66 | 2022 | |
| Novo Nordisk INC | $34.22 | 2022-2023 | Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $27.55 | 2024 | Arcalyst |
| Cvrx, INC. | $14.59 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $14.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2022 | |
| Tactile Systems Technology INC | $13.10 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.